Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy Pharmaceutical TechnologyCellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan's TSC-101 therapy in AML and MDS patients.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) Pharmaceutical Technology Cellares and TScan Therapeutics have entered a deal to assess automated manufacturing for TScan’s TSC-101 therapy in AML and MDS patients. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: A Spanish biotech banks $87M to make differentiated ADCsNext: Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership Related Stories Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026
